Longitudinal modeling to predict vital capacity in amyotrophic lateral sclerosis. Issue 3 (3rd April 2018)

• Record Type: Journal Article
• Authors: Jahandideh, Samad; Taylor, Albert A.; Beaulieu, Danielle; Keymer, Mike; Meng, Lisa; Bian, Amy; Atassi, Nazem; Andrews, Jinsy; Ennist, David L.
• Is Part Of: Amyotrophic lateral sclerosis and frontotemporal degeneration. Volume 19:Issue 3/4(2018)
• Page Start: 294
• Page End: 302
• Publication Date: 2018-04-03
• Subjects: Predictive modeling -- PRO-ACT -- neurodegenerative disease -- ALS -- vital capacity; 616.839
• DOI: 10.1080/21678421.2017.1418003
• Languages: English
• ISSNs: 2167-8421

Abstract

Abstract: Objectives : Death in amyotrophic lateral sclerosis (ALS) patients is related to respiratory failure, which is assessed in clinical settings by measuring vital capacity. We developed ALS-VC, a modeling tool for longitudinal prediction of vital capacity in ALS patients. Methods : A gradient boosting machine (GBM) model was trained using the PRO-ACT (Pooled Resource Open-access ALS Clinical Trials) database of over 10, 000 ALS patient records. We hypothesized that a reliable vital capacity predictive model could be developed using PRO-ACT. Results : The model was used to compare FVC predictions with a 30-day run-in period to predictions made from just baseline. The internal root mean square deviations (RMSD) of the run-in and baseline models were 0.534 and 0.539, respectively, across the 7L FVC range captured in PRO-ACT. The RMSDs of the run-in and baseline models using an unrelated, contemporary external validation dataset (0.553 and 0.538, respectively) were comparable to the internal validation. The model was shown to have similar accuracy for predicting SVC (RMSD = 0.562). The most important features for both run-in and baseline models were "Baseline forced vital capacity" and "Days since baseline." Conclusions : We developed ALS-VC, a GBM model trained with the PRO-ACT ALS dataset that provides vital capacity predictions generalizable to external datasets. The ALS-VC model could be helpful in advising and counseling patients, and, in clinical trials, it could be used to generate virtual control arms against which observed outcomes could be compared, or used to stratify patients into slowly, average, and rapidly progressing subgroups.